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Kawasaki disease (KD) is an acute systemic vasculitis in children associated with increased inflammatory cytokines and immune-regulatory abnormalities. 1 While the underlying cause of KD is unknown, recent studies have implicated several types of immune cells in KD etiology. In the acute phase of KD, CD14 + CD16
+ activated monocytes induce several inflammatory cytokines via activation of nuclear factor kappa B (NFjB). [2] [3] [4] T-helper type 17 (Th17) and regulatory T (T reg ) cells have also been reported to regulate inflammation in the acute phase of KD. [5] [6] [7] [8] Th17 cells are associated with tissue damage and autoimmunity, while T reg cells have an antagonistic effect and suppress inflammatory responses. In addition to immune cells, several types of inflammatory cytokines are produced in acute KD. Of particular importance is tumor necrosis factor (TNF)-a, a cytokine shown to induce inflammation in patients with KD. 9 Serum TNF-a and soluble TNF receptor 1 were found to be significantly elevated in patients with acute KD. [9] [10] [11] Infliximab (IFX) is a monoclonal antibody that binds to TNF-a and blocks its biological activity. I.v. IFX is used to treat several chronic inflammatory diseases, and has recently been used as a novel therapy for refractory KD. 12 IFX was found to be safe and well tolerated as a second-line treatment for i.v. immunoglobulin (IVIG)-resistant KD. 13 IFX is reported to downregulate the transcription of genes targeted by inflammatory signaling pathways related to KD, such as those pathways involving interleukin (IL)-1, IL-6, and TNF-a. 14 The effect of IFX on immune cells, however, remains unknown. To further investigate the mechanism of action of IFX, we examined changes in the abundance of activated monocytes, T reg cells, and Th17 cells in KD patients following treatment with IFX.
Methods

Subjects
This study involved 13 patients who were treated with IFX for IVIG-resistant KD between April 2013 and December 2015 at University of Yamanashi Hospital. The diagnosis was made according to the criteria of the Diagnostic Guidelines for Kawasaki Disease (5th revision), published by the Kawasaki Disease Research Committee in Japan. 15 All patients were given two or three cycles of IVIG (2 g/kg/ dose) with oral aspirin (30 mg/kg/day), but they had resistance to IVIG therapy and were therefore subsequently treated with one dose of IFX (5 mg/kg) infused over 2 h. We defined resistance to therapy as the presence of persistent or recurrent fever lasting >24 h after IVIG or IFX treatment was completed.
Two-dimensional echocardiography was performed to measure the internal diameter of the left main trunk coronary artery, proximal left anterior descending coronary artery, and right coronary artery. The diameter is expressed as a Z-score (SD units from the mean normalized for body surface area; normal Z-score <2.5). The examination was performed at baseline and at 1 and 3 months after IFX treatment.
The use of IFX for IVIG-resistant KD and the study design were both approved by the ethics committees of the University of Yamanashi Hospital. Written informed consent was obtained from the parents of all patients.
Laboratory procedure
Blood samples were obtained before and after IFX treatment. C-reactive protein (CRP), total leukocyte count, and fractional neutrophil, lymphocyte, and monocyte count were measured using automated cell count by standard techniques. Serum IL-6, soluble IL-2 receptor (soluble IL-2R) and TNF-a were measured using an enzyme-linked immunosorbent assay commercial kit (SRL, Inc., Tokyo, Japan). + monocytes, T reg cells and Th17 cells were measured using a flow cytometry method developed at the present laboratory. 16 Peripheral blood was obtained using ethylenediamine tetra-acetic acid 2Na as an anti-coagulant. Peripheral blood mononuclear cells (PBMC) were isolated for flow cytometry using a Ficoll density gradient. PBMC were suspended in Stain Buffer at a concentration of 1 9 10 6 cells/ mL. Cells were immunostained for 20 min at room temperature in the dark using fluorescein isothiocyanate (FITC)-conjugated anti-human CD4 for Th17 analysis or FITC-conjugated anti-human CD4 and phycoerythrin (PE)-conjugated antihuman CD25 for T reg analysis. After surface staining, cells were fixed, permeabilized, and stained with Alexa Fluor647-conjugated anti-human IL-17A for Th17 detection or Alexa Fluor647-conjugated anti-human forkhead box P3 (FOXP3) for T reg detection. For analysis of monocytes, PBMC suspended in phosphate-buffered saline were immunostained for 30 min at 4°C in the dark with PE-conjugated anti-human CD14 and FITC-conjugated anti-human CD16. After centrifugation, cells were washed twice with Stain Buffer and resuspended in Stain Buffer. Stained cells were analyzed on flow cytometry. All solutions and antibodies were purchased from BD Pharmingen, San Jose, CA, USA.
Statistical analysis
All data are expressed as mean AE SD. Paired Wilcoxon test was used to detect changes within treatment groups. Differences between treatments were detected using the Student t-test. P < 0.05 was defined as significant.
Results
Patient characteristics
The IFX treatment was performed at a median age of 34 months (range, 17-62 months). Mean time to first IVIG treatment was 4.6 AE 0.9 days (range, 3-6 days), while the mean time to IFX treatment was 9.4 AE 3.2 days (range, 7-19 days). Four patients had transient dilation of one or more coronary arteries. Four patients had IFX resistance and received plasma exchange as an additional treatment. Blood samples were obtained on the day of starting IFX and at a median of day 2 (range, 1-6 days) after the end of IFX therapy.
Effects of IFX
Overall circulating peripheral blood cells and CRP
Absolute white blood cell (WBC) count and CRP decreased significantly after IFX treatment. (Table 4) .
Plasma cytokine concentration
Serum soluble IL-2R and IL-6 decreased significantly after IFX treatment. Serum TNF-a increased significantly after IFX treatment ( Table 5) .
Effect of IFX response
In patients who were IFX resistant, there was no significant change in CD14 (Table 6) . (Table 7) .
Discussion
In patients with KD, circulating TNF-a is significantly elevated and is involved in the development of coronary artery aneurysms. [9] [10] [11] The blocking of TNF-a activity is therefore critical to the regulation of inflammation in KD.
T-helper type 17 and T reg cells have recently been reported to have an important role in the induction of systemic vasculitis during the acute phase of KD. [5] [6] [7] [8] [17] [18] [19] Th17 cells can produce IL-17 and lead to tissue damage and autoimmunity. IL-17, another pro-inflammatory cytokine, acts on a broad range of cell types, including neutrophils, monocytes, and fibroblasts, to induce the expression of other pro-inflammatory cytokines such as IL-6, TNF-a, and IL-8. 20 T reg cells secrete anti-inflammatory cytokines such as IL-10 and transforming growth factor (TGF)-b. In contrast to Th17 cells, T reg cells negatively regulate the inflammatory response. In addition to Th17 cells, CD14 + CD16 + activated monocytes have also been shown to increase in the acute phase of KD. 2, 3 Classical CD14 + CD16
À monocytes, which comprise the majority of monocytes, act as scavengers toward apoptotic cells and assist in resolving inflammation. In contrast, a minor subset of cells known as CD14 + CD16 + monocytes activates NFjB. NFjB is a pivotal transcription factor for genes that encode pro-inflammatory cytokines, including TNF-a, IL-6, and chemokines. 4 Overall, it is thought that an overproduction of inflammatory cytokines, induced by an imbalance among Th17 cells, T reg cells, and monocytes, plays an important role in the initiation stage of KD.
In recent years, the immunomodulatory effects of IVIG in patients with KD have been reported in several studies. CD14 + CD16
+ monocytes and NFjB activation were found to decrease after IVIG therapy.
2-4 IVIG treatment also reduced the proportion of Th17 cells, as well as the expression of IL-17. IVIG has been shown to increase T reg proportions and expression of FOXP3 in the acute phase of KD. 6, 8, 17 Furthermore, IVIG treatment in combination with IFX was found to increase the number of T reg cells in patients with KD. 21 The therapeutic effect of IFX alone on immune cells, however, is still unclear.
In this study we investigated the immunomodulatory effect of IFX, a second-line treatment for KD in IVIGresistant patients. 2, 6 For T reg cells, however, the T reg cell/CD4 + cell ratio was almost in the normal range according to previous studies: 8.15 AE 2.6%. 6 In the day following IFX treatment, patients whose CD14 + CD16 + monocytes had been elevated at baseline had a significant decrease toward the normal range (Tables 2,3) . Serum IL-6 was also significantly decreased as a result of IFX treatment (Table 5) . Absolute T reg cell count significantly increased after IFX treatment (Table 4) . Unexpectedly, however, the increased higher Th17 count observed at baseline was further increased, despite IFX treatment (Table 4) .
Infliximab has been reported to function through multiple mechanisms, including (i) neutralizing soluble TNF-a; (ii) dissociating TNF-a from its receptor; and (iii) efficiently killing TNF-a-producing macrophages and activated T cells through antibody-dependent or complement-dependent cytotoxicity. 22 Given the pharmacological effects of IFX, we speculate that IFX suppresses CD14 + CD16 + activated monocytes and upregulates T reg cells as follows. In previous studies of IVIG therapy, IL-17A and retinoic acid-related orphan receptor ct (RORct) expression increased before IVIG therapy. The increased IL-17A and RORct expression persisted in the same range for 3 weeks 8 or began to decrease at 7-10 days after IVIG therapy. 6, 18 Unlike the dynamics of Th17 cells in previous studies, in the present study the Th17 cell count was significantly increased after IFX treatment. In inflammatory arthritis, anti-TNF-a therapy leads to an increase in frequency of circulating Th17 cells. The mechanism of increase in Th17 cells may be due to the redistribution of inflammatory cells or influence of another substance, but the details are unclear. 23, 24 Also in KD, TNF-a inhibition might be associated with the activation of Th17 cells and production of IL-17. We speculate that the change in CD14 + CD16 + monocytes and in T reg cells, rather than changes in Th17 cells, plays a greater role in IFX treatment. It may therefore be possible to increase the therapeutic effect of IFX by using new drugs that suppress the increase of Th17 cells in combination with IFX.
In addition to immune cell abundance, we also measured soluble IL-2R, IL-6 and TNF-a. Activated T cells lead to the appearance of IL-2R and the release of IL-2R fragments, known as soluble IL-2R, into circulation. 25 IL-6 and TNF-a were also previously found to be secreted by activated monocytes and T cells. 20 We hypothesized that the decreased serum IL-6 and soluble IL-2R was due to IFX-induced activation of caspase-dependent apoptosis for activated T lymphocytes and monocytes. Serum TNF-a level, however, did not change following IFX treatment. One possible explanation is that serum TNF-a level can be attributed to biologically inactive TNF-a/anti-TNF-a complexes, which can still be detected by the enzyme-linked immunoassay for TNF-a antigen. 26 In this study, we were unable to detect an IFX-induced decrease in either the absolute count or the relative percentage of CD14 +
CD16
+ monocytes in all patients. In some patients, CD14 + CD16
+ monocytes were already within the normal range prior to IFX treatment. Further large-scale studies will likely be needed to better assess more subtle changes in CD14 + CD16
+ monocytes. There are potential limitations to this study. First, we did not quantify the mRNA expression of RORct in Th17 cells, and FOXP3 in T reg cells was not quantified. Second, we did not measure the profile of cytokines, such as IL-17, IL-10 and TGF-b, produced by Th17 cells and T reg cells. It will also be necessary to determine why Th17 cells increased following IFX treatment. Finally, this study involved short-term IFX treatment, therefore additional studies are required to clarify the longer-term effects of IFX in KD.
In conclusion, IFX may regulate activated monocytes and T reg cells toward the normal range in the process of attenuating inflammation. The interactions between activated monocytes and T reg cells may play an important role in the development or prevention of inflammation in the acute phase of KD.
